This process of developing EBM-based guidelines and applying them to clinical care highlights the tension between generating unbiased knowledge based on statistical aggregation and the application of this information to individual patients.
The FDA’s expanded access pathway allows patients with no other therapeutic options to request access to investigational agents, but manufacturers do not often grant it.
AMA J Ethics. 2015;17(12):1142-1146. doi:
10.1001/journalofethics.2015.17.12.stas1-1512.
Geoff Hollett, PhD and Jennie B. Jarrett, PharmD, PhD, MMedEd
The Strategic National Stockpile is a national system maintained by the US federal government to deliver medical supplies during emergencies, and it needs administrative changes.
AMA J Ethics. 2024;26(4):E315-320. doi:
10.1001/amajethics.2024.315.
Wejdan Bagais joins Ethics Talk to discuss her article, coauthored with Matt Christian: “Which Data Analytics Tool Should We Use to Evaluate Risk in Upstream Drug Supply Chains?”
Nisha Quasba joins Ethics Talk to discuss her article, coauthored with Elliot Vice: “What Should Prescribers and Policy Makers Know About US Drug Importation?”